Information Provided By:
Fly News Breaks for March 12, 2018
BMY, MRK
Mar 12, 2018 | 06:27 EDT
Leerink analyst Seamus Fernandez upgraded Merck (MRK) to Outperform from Market Perform with an unchanged price target of $66. The shares closed Friday up 38c to $55.14. Keytruda will continue to dominate the first-line non-small cell lung cancer market, Fernandez tells investors in a research note. Following his firm's lung cancer survey, the analyst believes Merck will deliver upside to consensus Keytruda estimates along with positive earnings leverage in the second half of 2018 and 2019. He thinks KN-189 likely will show a clinically meaningful overall survival benefit for the Keytruda plus chemo combo in all patients, including a strong benefit in patients with moderate or low PD-L1 biomarker levels. Fernandez does not believe Bristol-Myers' (BMY) Opdivo and Yervoy combo will supplant Keytruda as the market leader. The analyst thinks now is the time to own shares of Merck.
News For MRK;BMY From the Last 2 Days
MRK
Mar 28, 2024 | 06:48 EDT
Merck announced that the European Commission has approved Keytruda, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
MRK
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 08:55 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Robinhood (HOOD)... To see the rest of the story go to thefly.com. See Story Here
MRK
Mar 27, 2024 | 07:19 EDT
BofA notes that Merck shares have been volatile as investors have contemplated various scenarios regarding the approval of sotatercept and its language, including "a lot of investor angst" given the risk for the FDA to issue either black box warnings, REMS, and/or monitoring requirement. However, sotatercept's approval in PAH with the brand name Winrevair "comes with a squeaky-clean label," without WHO functional class restriction or a need to be on background therapy, no black box and no REMS, which represents "the most bullish scenario," the analyst tells investors. The firm, which anticipates Merck shares to react favorably, maintains a Buy rating and $135 price target and sees upside to sotatercept's commercial outlook.
MRK
Mar 27, 2024 | 06:12 EDT
Wells Fargo raised the firm's price target on Merck to $135 from $130 and keeps an Equal Weight rating on the shares. The firm notes WINREVAIR, or sotatercept, was approved with simple monitoring on the label, removing an overhang on the stock. $242k annual pricing is competitive and could enable the drug to move into earlier lines, and Wells now models $7B peak sales opportunity.